Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.50 |
| ▸ | PPARD | Q03181 | 3/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2113930 | 0.88 | PPARD (0.52) | PTGDR2PPARDPPARARXRARXRB | |
| SCHEMBL18794840 | 0.86 | PDK2 (0.46) | FFAR4SLC13A3TDP1L3MBTL1TACR1 | |
| SCHEMBL18794874 | 0.83 | PDK2 (0.48) | PPARDPPARASLC13A3TACR1 | |
| SCHEMBL5274567 | 0.82 | ALOX15 (0.54) | MCL1TDP1ALOX15 | |
| SCHEMBL18794839 | 0.81 | PSEN1 (0.53) | FFAR4SLC13A3TDP1L3MBTL1TACR1 | |
| SCHEMBL17896578 | 0.81 | SMN1; SMN2 (0.58) | PTGDR2PPARDPPARARXRARXRB | |
| SCHEMBL12527817 | 0.81 | PPARD (0.49) | PTGDR2PPARDPPARARXRARXRB | |
| SCHEMBL14258069 | 0.81 | ALDH1A1 (0.47) | PTGDR2PPARDPPARARXRARXRB | |
| SCHEMBL18056097 | 0.78 | RXRA (0.50) | PTGDR2PPARDPPARARXRARXRB | |
| SCHEMBL585546 | 0.75 | KDM4E (0.68) | PTGDR2PPARAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220098154-A1 | ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2022-03-31 | — | — | US | disclosed |
| EP-3917627-A1 | ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | Ideaya Biosciences, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020160134-A1 | ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160134-A1 | ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| US-20200181067-A1 | FLUORINATED AMIDE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | TRILLIUM THERAPEUTICS INC. (CA) | 2020-06-11 | — | — | US | disclosed |
| US-20200181067-A1 | FLUORINATED AMIDE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | TRILLIUM THERAPEUTICS INC. (CA) | 2020-06-11 | — | — | US | disclosed |
| US-10604476-B2 | Fluorinated amide derivatives and their uses as therapeutic agents | TRILLIUM THERAPEUTICS INC. (CA) | 2020-03-31 | — | — | US | disclosed |
| US-20180334425-A1 | FLUORINATED AMIDE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-11-22 | — | — | US | disclosed |
| EP-3368509-A1 | FLUORINATED AMIDE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | Trillium Therapeutics Inc. (CA) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017070795-A1 | FLUORINATED AMIDE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | TRILLIUM THERAPEUTICS INC. (CA) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017070795-A1 | FLUORINATED AMIDE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | TRILLIUM THERAPEUTICS INC. (CA) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098154-A1 | ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | POLQ, POLH, POLB | PTGDR2 2227/4885PPARD 1196/4885PPARA 891/4885 |
| US-20180334425-A1 | FLUORINATED AMIDE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | GRIN2A, ACHE, BDNF | PTGDR2 200/4885PPARD 293/4885PPARA 337/4885 |
| US-10604476-B2 | Fluorinated amide derivatives and their uses as therapeutic agents | GRIN2A, ACHE, BDNF | PTGDR2 200/4885PPARD 293/4885PPARA 337/4885 |
| US-20200181067-A1 | FLUORINATED AMIDE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | GRIN2A, ACHE, BDNF | PTGDR2 200/4885PPARD 293/4885PPARA 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.